J&J Acquires Actelion for $$30 Billion

The transcript discusses J&J's acquisition attempts of Actelion, highlighting the initial bidding process, the collapse of negotiations, and the eventual return to the table with a higher offer. The market reacted positively to the news, with Actelion's stock price significantly increasing. J&J's strategic goal was to enter the rare disease market, particularly focusing on Actelion's treatments for rare blood pressure conditions. The lack of competitors and J&J's strong financial position facilitated the acquisition process.

What were the circumstances that led to the deal falling apart between J&J and Actelion?

How did the stock price of Actelion change from February to the time of the deal?

What was the industrial logic behind J&J's interest in acquiring Actelion?

What advantages did J&J have in pursuing the acquisition of Actelion?

What is the significance of J&J's investment grade rating in the context of the acquisition?